Company

TetraLogic Pharmaceuticals

As of the edition of 20 October 2026, TetraLogic Pharmaceuticals runs 4 drugs; it is on route A at 4 targets and on route B at 0 targets.

Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.

Family history

TetraLogic Pharmaceuticals was dissolved.

  • TetraLogic Pharmaceuticals: dissolved

Drugs by status

StatusCount
Went quiet2
Stopped2
Total4

Where it needs a new molecule

Route A at 4 targets, route B at 0 targets.

Three of its 4 rows, by target and route
TargetRoute
BIRC3 Baculoviral IAP repeat-containing protein 3Route A
BIRC2 Baculoviral IAP repeat-containing protein 2Route A
HDAC9 Histone deacetylase 9Route A

All 4 rows on route A or B

In the product

4 company-target rows on route A or B; 1 is not shown here, and no score is.

Where its trials are

  • Cancer: 5 trials led
  • Blood and lymph: 3 trials led
  • Immune system: 2 trials led